Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.82 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25009811 | 0.96 | L3MBTL1 (0.82) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL28833898 | 0.94 | LMNA (0.74) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL18668975 | 0.94 | LMNA (0.74) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL30556174 | 0.93 | L3MBTL1 (0.76) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL25009812 | 0.93 | L3MBTL1 (0.76) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL29040282 | 0.92 | LMNA (0.76) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL28174525 | 0.92 | LMNA (0.76) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL29155474 | 0.92 | LMNA (0.72) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL551811 | 0.92 | LMNA (0.97) | LMNAL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL28174523 | 0.92 | LMNA (0.76) | LMNAL3MBTL1MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023010200-A1 | THERAPEUTIC COORDINATION POLYMERS CONTAINING PHARMACEUTICALS FOR DRUG RELEASE APPLICATIONS | UNIVERSITY OF WINDSOR (CA) | 2023-02-09 | — | — | WO | disclosed |
| US-11180521-B2 | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof | METRO INTERNATIONAL BIOTECH, LLC (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210032280-A1 | NICOTINAMIDE RIBOSIDE ANALOGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | METRO INTERNATIONAL BIOTECH, LLC | 2021-02-04 | — | — | US | disclosed |
| WO-2019152416-A1 | NICOTINAMIDE RIBOSIDE ANALOGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | METRO INTERNATIONAL BIOTECH, LLC (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032280-A1 | NICOTINAMIDE RIBOSIDE ANALOGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | NAMPT, NADK, NNT | LMNA 1520/4885L3MBTL1 4664/4885MAPT 919/4885 |
| US-11180521-B2 | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof | NAMPT, NADK, NNT | LMNA 1520/4885L3MBTL1 4664/4885MAPT 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.